ராபர்ட் திரேசெர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ராபர்ட் திரேசெர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ராபர்ட் திரேசெர் Today - Breaking & Trending Today

JAVELIN Bladder 100 Trial - Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma


JAVELIN Bladder 100 Trial
Interviews with Experts at Conferences
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
April 23, 2021
November 17, 2020
November 16, 2020
October 14, 2020
Conference Coverage
Conference Highlights from Recent Conference Coverage
Petros Grivas, MD, PhD
In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More
Yohann Loriot, MD, PhD
Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reporte ....

United States , Elizabeth Plimack , Petros Grivas , Shaheen Alanee , Juergen Gschwend , Matthew Galsky , Thomasb Powles , Norihiko Tsuchiya , Srikala Sridhar , Robert Dreicer , Yohann Loriot , Thomas Powles , European Society Of Medical Oncology , European Multidisciplinary Congress On Urological Cancers , Society Of Urologic Oncology , Virtual Congress , Southeast Section , Neal Shore , Urologic Oncology , Annual Virtual Meeting , Bladder Cancer , European Multidisciplinary Congress , Urological Cancers , European Society , Medical Oncology , Kilian Gust ,

Second look analysing prostate cancer study data reaps new rewards


Dr Maha Hussain at the recent virtual ASCO Meeting. Credit: ASCO
Second look analysing prostate cancer study data reaps new rewards
Two studies unveiled at last month’s virtual Genitourinary Cancers Symposium, organised by the American Society of Clinical Oncology, will have implications for both the treatment of prostate cancer and the provision of screening,
Peter Doyle reports
In men with non-metastatic castration-resistant prostate cancer (nmCRPC) and rapidly rising prostate specific antigen (PSA) treated with androgen deprivation therapy (ADT) plus enzalutamide (ENZA), there was a close relationship between the degree of PSA decline and survival outcomes, according to a newly published post-hoc analysis of the PROSPER trial. ....

United States , Maha Ha Hussain , Vidit Sharma , Robert Dreicer , Peter Doyle , Us Preventive Services Task Force , University Of California Los Angeles , American Society Of Clinical Oncology , American Association Of Central Cancer Registries , Genitourinary Cancers Symposium , American Society , Clinical Oncology , Efficacy Study , Services Task Force , North American Association , Central Cancer Registries , Behavioral Risk Factor Surveillance System , California Los , ஒன்றுபட்டது மாநிலங்களில் , மஹா எச்ஏ ஹுசைன் , வீதித் ஷர்மா , ராபர்ட் திரேசெர் , பீட்டர் டாய்ல் , எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி படை , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா லாஸ் ஏஞ்சல்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,

Drop in PSA Screening, Increase in Metastatic Prostate Cancers